1. Home
  2. NVVEW vs ZLAB Comparison

NVVEW vs ZLAB Comparison

Compare NVVEW & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVVEW
  • ZLAB
  • Stock Information
  • Founded
  • NVVEW N/A
  • ZLAB 2013
  • Country
  • NVVEW China
  • ZLAB Cayman Islands
  • Employees
  • NVVEW N/A
  • ZLAB N/A
  • Industry
  • NVVEW Oil Refining/Marketing
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVVEW Energy
  • ZLAB Health Care
  • Exchange
  • NVVEW Nasdaq
  • ZLAB Nasdaq
  • Market Cap
  • NVVEW N/A
  • ZLAB 3.5B
  • IPO Year
  • NVVEW 2020
  • ZLAB 2017
  • Fundamental
  • Price
  • NVVEW $0.02
  • ZLAB $32.53
  • Analyst Decision
  • NVVEW
  • ZLAB Buy
  • Analyst Count
  • NVVEW 0
  • ZLAB 4
  • Target Price
  • NVVEW N/A
  • ZLAB $47.37
  • AVG Volume (30 Days)
  • NVVEW N/A
  • ZLAB 1.6M
  • Earning Date
  • NVVEW N/A
  • ZLAB 05-08-2025
  • Dividend Yield
  • NVVEW N/A
  • ZLAB N/A
  • EPS Growth
  • NVVEW N/A
  • ZLAB N/A
  • EPS
  • NVVEW N/A
  • ZLAB N/A
  • Revenue
  • NVVEW N/A
  • ZLAB $398,988,000.00
  • Revenue This Year
  • NVVEW N/A
  • ZLAB $45.57
  • Revenue Next Year
  • NVVEW N/A
  • ZLAB $47.91
  • P/E Ratio
  • NVVEW N/A
  • ZLAB N/A
  • Revenue Growth
  • NVVEW N/A
  • ZLAB 49.59
  • 52 Week Low
  • NVVEW N/A
  • ZLAB $15.00
  • 52 Week High
  • NVVEW N/A
  • ZLAB $39.77
  • Technical
  • Relative Strength Index (RSI)
  • NVVEW N/A
  • ZLAB 51.76
  • Support Level
  • NVVEW N/A
  • ZLAB $28.34
  • Resistance Level
  • NVVEW N/A
  • ZLAB $33.45
  • Average True Range (ATR)
  • NVVEW 0.00
  • ZLAB 2.34
  • MACD
  • NVVEW 0.00
  • ZLAB -0.02
  • Stochastic Oscillator
  • NVVEW 0.00
  • ZLAB 61.00

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Share on Social Networks: